echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Over 2 billion anti-ED drugs, another pharmaceutical company enters the market

    Over 2 billion anti-ED drugs, another pharmaceutical company enters the market

    • Last Update: 2021-07-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Medical Network, February 24 News On February 22, Neptunus Biopharmaceuticals issued an announcement stating that sildenafil citrate tablets (50mg, 100mg) of the holding subsidiary Shenzhen Neptunus Medicine have been approved for listing
    .
    Sildenafil is a mainstream anti-ED drug.
    According to Meinenet data, in 2019, the sales of sildenafil in physical pharmacies in cities in China exceeded 2.
    3 billion yuan, a year-on-year increase of 7.
    42%
    .
    Sildenafil Citrate Tablets is used to treat erectile dysfunction (ED) and is a selective inhibitor of phosphodiesterase type 5 (PDE-5) developed by Pfizer
    .
    PDE-5 inhibitor drugs are the main anti-ED products.
    Sildenafil, tadalafil, and vardenafil are the three main PDE-5 inhibitors in the global market
    .
    The sales of sildenafil at physical pharmacies in cities in China (unit: 10,000 yuan) Source: Mynet.
    com Competitive pattern of sildenafil at physical pharmacies in cities in China In the physical pharmacy market, sildenafil is the leading product of urinary systemic drugs
    .
    According to data from Menet.
    com, in 2019, the sales of sildenafil at the physical pharmacy terminal in Chinese cities exceeded 2.
    3 billion yuan, a year-on-year increase of 7.
    42%
    .
    Among them, Baiyunshan Pharmaceutical General Factory ranked first with 48.
    77% market share, followed by the original research manufacturer Pfizer with 46.
    52%
    .
    The brand pattern of Sildenafil in China's urban physical pharmacies in 2019.
    Source: Mynet.
    com.
    Chinese urban physical pharmacies.
    The competitive structure of sildenafil.
    Currently, the domestically marketed sildenafil dosage forms include ordinary tablets and orally disintegrating tablets, and sildena citrate.
    Only the original manufacturer of non-orally disintegrating tablets is approved by Pfizer, and the manufacturers of Sildenafil Citrate tablets include Pfizer, Baiyunshan, Yabang Epson, Diao Pharmaceutical, Jinheng Pharmaceutical, Changshan Pharmaceutical, Qilu Pharmaceutical , Langsheng Pharmaceutical and Neptunus Pharmaceuticals and other 9 companies
    .
    The listing application of sildenafil citrate tablets is under review and approval.
    Source: One-click search on Mynet.
    com Although sildenafil has been included in the third batch of centralized procurement, there are still many domestic pharmaceutical companies applying for imitation
    .
    Yangtze River Pharmaceutical, Dongyang Sunshine Pharmaceutical, Guangshengtang Pharmaceutical, China Resources Secco Pharmaceutical.
    .
    .
    7 pharmaceutical companies submitted applications for the listing of sildenafil citrate tablets according to the new registration classification and are under review and approval
    .
    Source: Mi Nei.
    com database Note: Mi Nei.
    com China's urban entity pharmacy terminal competition pattern database is an enlarged version of urban entity pharmacies that covers 293 prefectures and above cities across the country (excluding county and rural entity pharmacies), and continuously monitors all categories Database
    .
    The above sales are calculated based on the average retail price of the product at the terminal
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.